{"organizations": [], "uuid": "f17b9a5ea2c213e12f7765ae506fbcbd8401a0cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immupharma-announces-topline-resul/brief-immupharma-announces-topline-results-of-lupuzor-pivotal-phase-iii-trial-idUSFWN1RU01E", "country": "US", "domain_rank": 408, "title": "BRIEF-Immupharma Announces Topline Results Of Lupuzor Pivotal Phase III Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.776, "site_type": "news", "published": "2018-04-17T15:58:00.000+03:00", "replies_count": 0, "uuid": "f17b9a5ea2c213e12f7765ae506fbcbd8401a0cf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immupharma-announces-topline-resul/brief-immupharma-announces-topline-results-of-lupuzor-pivotal-phase-iii-trial-idUSFWN1RU01E", "ord_in_thread": 0, "title": "BRIEF-Immupharma Announces Topline Results Of Lupuzor Pivotal Phase III Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "immupharma plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - ImmuPharma PLC:\n* LUPUZOR DEMONSTRATED SUPERIOR RESPONSE RATE OVER PLACEBO IN PRIMARY ANALYSIS ON FULL ANALYSIS SET OF ALL 202 PATIENTS\n* SUPERIOR RESPONSE DID NOT ALLOW STATISTICAL SIGNIFICANCE TO BE REACHED (P = 0.2631) AND TRIALâ€™S PRIMARY END POINT WAS NOT MET\n* IN PATIENTS WHO HAD ANTI-DSDNA AUTOANTIBODIES LUPUZOR DEMONSTRATED A SUPERIOR RESPONSE RATE OVER PLACEBO\n* STUDY CONFIRMED SAFETY PROFILE OF LUPUZOR WITH ZERO SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T15:58:00.000+03:00", "crawled": "2018-04-18T18:24:04.022+03:00", "highlightTitle": ""}